SynAct Pharma Year-end Report 2025

“As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical execution, corporate development and external validation. Our focus remains firmly on advancing resomelagon (AP1189), our potential first-in-class non-suppressive therapy for inflammatory diseases, toward meaningful clinical and strategic value creation.”

Jeppe Øvlesen
Chief Executive Officer and Board Member

Fourth quarter 2025 (October – December)

• The Group’s net sales amounted to SEK 0 (0) thousand.
• Operating expenses amounted to SEK 22,720 (20,797) thousand, an increase of 9%.
• The Group’s loss after tax amounted to SEK 22,929 (18,379) thousand.
• The Group’s earnings per share before and after dilution amounted to -0.43 (-0.44) SEK.
• Cash flow from operating activities amounted to SEK -23,965 (-17,779) thousand.
• Cash flow from financing activities amounted to SEK -147 (40,199) thousand.
• Cash flow for the period amounted to SEK -24,112 (22,420) thousand.
• Cash and cash equivalents at the end of the period amounted to SEK 53,405 (61,209) thousand. 

Twelve months 2025 (January – December) 

• The Group’s net sales amounted to SEK 0 (0) thousand.
• Operating expenses amounted to SEK 116,540 (89,980) thousand, an increase of 29%.
• The Group’s loss after tax amounted to SEK 110,826 (82,401) thousand.
• The Group’s earnings per share before and after dilution amounted to -2.17 (-2.08) SEK.
• Cash flow from operating activities amounted to SEK -97,330 (89,197) thousand.
• Cash flow from financing activities amounted to SEK 90,458 (87,405) thousand.
• Cash flow for the period amounted to SEK -6,872 (-1,792) thousand.

Significant events during the fourth quarter

• Oct 29 – Notice of Extraordinary General Meeting of SynAct Pharma AB on November 27, 2025.
• Nov 3 – 190 patients randomized in SynAct Pharma’s Phase 2b study ADVANCE.
• Nov 27 – Report from the Extraordinary General Meeting of SynAct Pharma AB.
• Dec 11 – Nomination committee appointed ahead of AGM 2026 in SynAct Pharma AB.
• Dec 22 – SynAct Pharma management and Chairman of the Board have acquired shares.
• Dec 23 – SynAct Pharma Board of Directors and Management Enter Lock-up Agreements.

Significant events after the end of the period

• Jan 9 – The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares.
• Jan 19 – SynAct Pharma appoints Malin Wikstrand as interim CFO.
• Jan 30 – SynAct Pharma initiates Phase 2 study in respiratory insufficiency.
• Feb 6 – SynAct Pharma announces that recruitment goal was reached in the Phase 2b ADVANCE study.
• Feb 17 – Repurchase of shares in Synact Pharma AB.

For further information about SynAct Pharma AB, please contact:
Jeppe Øvelsen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67 
E-mail: joo@synactpharma.com  

Malin Wikstrand
Interim CFO, SynAct Pharma AB 
Phone: +46 735-045760
E-mail: MAW@synactpharma.com